This HTML5 document contains 60 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/chemspider/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/pdb/
n20http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/pubchem-substance/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB04690/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04690
rdf:type
n3:Drug
n3:description
An alkaloid isolated from the stem wood of the Chinese tree, <i>Camptotheca acuminata</i>. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. [PubChem]
n3:generalReferences
# Wall ME, Wani MC: Camptothecin and taxol: from discovery to clinic. J Ethnopharmacol. 1996 Apr;51(1-3):239-53; discussion 253-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9213622 # Kepler JA, Wani MC, McNaull JN, Wall ME, Levine SG: Plant antitumor agents. IV. An approach toward the synthesis of camptothecin. J Org Chem. 1969 Dec;34(12):3853-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5357525
n3:group
experimental
n3:indication
Investigated for the treatment of cancer.
owl:sameAs
n14:DB04690 n20:DB04690
dcterms:title
Camptothecin
adms:identifier
n6:Camptothecin n7:PA153590860 n8:24360 n9:46507644 n10:27656 n12:C01897 n15:EHD n16:22775 n17:DB04690
n3:mechanismOfAction
Camptothecin binds to the topoisomerase I and DNA complex (the covalent complex) resulting in a ternary complex, and thereby stabilizing it. This prevents DNA relegation and therefore causes DNA damage which results in apoptosis.
n3:synonym
D-camptothecin 21,22-Secocamptothecin-21-oic acid lactone Camptothecine 20(S)-Camptothecin (+)-camptothecine (s)-camptothecin (+)-camptothecin (s)-(+)-camptothecin
n3:toxicity
Acute oral toxicity (LD<sub>50</sub>) in mouse: 50.1 mg/kg
n3:synthesisReference
Tadashi Miyasaka, Seigo Sawada, Kenichiro Nokata, Masahiko Mutai, "Photochemical process for preparing camptothecin derivatives." U.S. Patent US4545880, issued March, 1976.
n18:hasConcept
n19:M0003242
n3:IUPAC-Name
n4:271B4A2B-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4A31-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4A30-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4A2D-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4A2E-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4A2F-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4A29-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4A42-363D-11E5-9242-09173F13E4C5 n4:271B4A27-363D-11E5-9242-09173F13E4C5 n4:271B4A2A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4A28-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4A37-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4A38-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4A32-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4A33-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4A35-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4A34-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4A36-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
7689-03-4
n3:category
n3:Bioavailability
n4:271B4A3D-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4A3F-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4A40-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4A41-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4A3C-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4A3B-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4A3E-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4A2C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4A39-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4A3A-363D-11E5-9242-09173F13E4C5